Sir. We present the case of a 48-year-old woman with a history of diffuse cutaneous systemic sclerosis (SSc) with prominent salt and pepper changes. In August 2015, she was diagnosed with SSc based on proximal skin thickening, Raynaud’s phenomenon with digital ulcers, abnormal nailfold capillary changes (giant capillaries and hemorrhages), esophageal dysmotility, and calcinosis. At the time of diagnosis, she also developed proximal muscle weakness and creatine kinase (CK) was elevated to 600 IU/L. She was prescribed prednisone and mycophenolate mofetil (MMF), which she intermittently took from 2015-2017. She was referred to our Center by November 2018 for progressive muscle weakness and skin tightening and was not on any therapy. On skin examination, her modified Rodnan skin score (mRSS) was 17 and she had prominent salt and pepper like changes on the anterior chest, forehead, and posterior neck. Muscle strength exam revealed proximal muscle weakness with neck flexors of 2/5, bilateral arm abductors 3/5, and hip flexors 2/5 on MRC scale. The remainder of the examination was unremarkable. CK was 142 IU/L. SSc specific antibodies were negative. Myositis panel was positive for U3-RNP (anti-fibrillarin). She underwent electromyography (EMG) which demonstrated severe non-irritable myopathy and bilateral thigh muscle magnetic resonance imaging (MRI-T2/STIR) demonstrated muscle edema. She declined muscle biopsy. Based on active skin disease and severe myopathy, MMF was initiated in December 2018 but ultimately discontinued due to gastrointestinal side effects. Intravenous immunoglobulin (IVIG) was started in March 2020 and within 4 months, she had improvement of her proximal muscle weakness and pepper changes of the skin (Figure 1). Intriguingly, there was also improvement of the mRSS (17 points to 8 points) and muscle strength (2/5 to 4+/5 in proximal muscles). Janus kinase (JAK) inhibitors such as tofacitinib have been reported to be efficacious in treating diffuse SSc and dermatomyositis in early phase clinical trials (1, 2). Barring rituximab has also been reported to be efficacious in the treatment of refractory arthritis in a patient with diffuse SSc (3). Recently, topical ruxolitinib was approved for the treatment of non-segmental vitiligo (4). Salt and pepper changes of the skin in SSc are thought to be due to areas of depigmentation where the perifollicular pigmentation remains intact. The proposed autoimmune mechanism is that the melanocytes in the perifollicular areas are spared (5) because the perifollicular sites have a better capillary system that can warm the perifollicular sites have a better capillary system that can warm the perifollicular pigmentation and thus pigmentation for these areas (6). The pathogenesis is thought to be similar to that of vitiligo where the JAK/STAT pathway has been implicated. JAKs transcribe cytokine-mediated signals which lead to activation of STAT1 and result in CXCL10 transcription (thought to be elevated in vitiligo patients) where JAK inhibitors, like tofacitinib, block cytokine signaling to induce re-pigmentation (7, 8). While our patient was on combination therapy with tofacitinib and IVIG, the improvement was clearly evident 3 months after initiation of tofacitinib. To our knowledge, this case is the first report of significant improvement in pigmentation after treatment with tofacitinib in diffuse SSc. However, it should be noted that the pigment change may have also occurred due to changes in disease control rather than direct effects of the tofacitinib. Nonetheless, JAK inhibitors may be a promising therapeutic agent for the treatment of salt and pepper depigmentation in patients with diffuse cutaneous SSc.

Fig. 1. On the left is a 48-year-old female before treatment with severe skin hypopigmentation and hyperpigmentation appearing with salt and pepper changes on her anterior chest, forehead, and face. After 8 months of treatment with tofacitinib, the right panel shows regeneration of affected skin in anterior chest, right anterior forehead, and cheeks.

A. NALLAPATI1
F.M. WHALEY, MD
J.J. PAIK2, MD, MHS
1Johns Hopkins University, Baltimore; 2Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Please address correspondence to:
Julie J. Paik,
5200 Eastern Avenue, Mason F. Lord, Center Tower, Suite 4300, Baltimore, MD 21224, USA.
E-mail: jpaik1@jhmi.edu
Funding. J.J. Paik is supported in part by K23AR073927.

Competing interests: none declared.
Letters to the Editors

References